Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop

(2016) P. Berraondo et al.   CANCER RESEARCH

Talimogene Laherparepvec for the Treatment of Advanced Melanoma

(2016) P. A. Ott et al.   CLINICAL CANCER RESEARCH

Emerging Opportunities and Challenges in Cancer Immunotherapy

(2016) T. L. Whiteside et al.   CLINICAL CANCER RESEARCH

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

(2016) M. V. Maus et al.   CLINICAL CANCER RESEARCH

Dendritic Cell-Based Immunotherapy: State of the Art and Beyond

(2016) K. F. Bol et al.   CLINICAL CANCER RESEARCH

PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor

(2016) L. Shi et al.   CLINICAL CANCER RESEARCH

In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing

(2016) S. Lehmann et al.   CLINICAL CANCER RESEARCH

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

(2016) Holbrook E. Kohrt et al.   Journal for ImmunoTherapy of Cancer

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

(2016) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

(2015) A. K. Nowak et al.   ANNALS OF ONCOLOGY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Defining dendritic cells

(2015) Barbara U Schraml et al.   CURRENT OPINION IN IMMUNOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating precursors of human CD1c+and CD141+dendritic cells

(2015) Gaëlle Breton et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model

(2015) Estanislao Nistal-Villan et al.   Molecular Cancer

In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf

(2015) Linda Hammerich et al.   Molecular Oncology

Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients

(2015) Timothy P Cripe et al.   MOLECULAR THERAPY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

(2015) A. R. Sanchez-Paulete et al.   Cancer Discovery

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade

(2015) José I. Quetglas et al.   Cancer Immunology Research

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

(2015) S. Van Lint et al.   Cancer Immunology Research

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

(2015) Nicola Mozzillo et al.   OncoImmunology

CD103+ Dendritic Cells Producing Interleukin-12 in Anticancer Immunosurveillance

(2014) Laurence Zitvogel et al.   CANCER CELL

Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells

(2014) Brian Ruffell et al.   CANCER CELL

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

(2014) Miranda L. Broz et al.   CANCER CELL

Strict Requirement for Vector-Induced Type I Interferon in Efficacious Antitumor Responses to Virally Encoded IL12

(2014) I. Melero et al.   CANCER RESEARCH

Intratumoral Immunization: A New Paradigm for Cancer Therapy

(2014) A. Marabelle et al.   CLINICAL CANCER RESEARCH

Batf3-dependent CD103+dendritic cells are major producers of IL-12 that drive local Th1 immunity againstLeishmania majorinfection in mice

(2014) María Martínez-López et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

(2014) Rituparna Das et al.   JOURNAL OF IMMUNOLOGY

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer

(2014) Marieke F. Fransen et al.   VACCINE

Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

(2014) T. Bald et al.   Cancer Discovery

T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

(2014) I. Melero et al.   Cancer Discovery

Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses

(2014) B. Weide et al.   Cancer Immunology Research

Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial

(2014) A. M. Salazar et al.   Cancer Immunology Research

New insights into the mechanism of action of immune checkpoint antibodies

(2014) Aurélien Marabelle et al.   OncoImmunology

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects

(2013) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

(2013) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4

(2013) Zamaneh Mikhak et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING

(2013) Xu Zhang et al.   MOLECULAR CELL

cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING

(2013) Andrea Ablasser et al.   NATURE

Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors

(2013) F. Sandoval et al.   Science Translational Medicine

Decisions About Dendritic Cells: Past, Present, and Future

(2012) Ralph M. Steinman   Annual Review of Immunology

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Oncolytic Virus and Anti-4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

(2012) L. B. John et al.   CANCER RESEARCH

Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

(2012) S. Adams et al.   CLINICAL CANCER RESEARCH

Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer

(2012) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects

(2012) Maria Grazia Ruocco et al.   JOURNAL OF CLINICAL INVESTIGATION

Intratumoral Delivery of Low Doses of Anti-CD40 mAb Combined With Monophosphoryl Lipid A Induces Local and Systemic Antitumor Effects in Immunocompetent and T Cell-Deficient Mice

(2012) Tyler J. Van De Voort et al.   JOURNAL OF IMMUNOTHERAPY

Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12

(2012) José I Quetglas et al.   MOLECULAR THERAPY

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective Activation of Oxygen-Deprived Tumor-Infiltrating Lymphocytes through Local Intratumoral Delivery of CD137 Monoclonal Antibodies

(2012) Cornelis J.M. Melief   Cancer Discovery

The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy

(2012) Asís Palazón et al.   Cancer Discovery

The convergence of radiation and immunogenic cell death signaling pathways

(2012) Encouse B. Golden et al.   Frontiers in Oncology

Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice

(2011) Sally M. Amos et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

(2011) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity

(2011) Taro Kawai et al.   IMMUNITY

Pathogen Recognition by the Innate Immune System

(2011) Himanshu Kumar et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Treatment of Locally Recurrent Mucosal Melanoma With Topical Imiquimod

(2011) Elizabeth C. Smyth et al.   JOURNAL OF CLINICAL ONCOLOGY

TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection

(2011) I. Jelinek et al.   JOURNAL OF IMMUNOLOGY

Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients

(2011) C. Alfaro et al.   JOURNAL OF IMMUNOLOGY

Carcinoma-Derived Interleukin-8 Disorients Dendritic Cell Migration Without Impairing T-Cell Stimulation

(2011) Carlos Alfaro et al.   PLoS One

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

(2010) Juan Dubrot et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

(2010) G. Schiavoni et al.   CANCER RESEARCH

Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10

(2010) Nancy Díaz-Valdés et al.   HEPATOLOGY

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Human CD141+(BDCA-3)+dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens

(2010) Sarah L. Jongbloed et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Characterization of human DNGR-1+BDCA3+leukocytes as putative equivalents of mouse CD8α+dendritic cells

(2010) Lionel Franz Poulin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immunology and Gene Therapy: Shoulder to Shoulder Into the Fray

(2010) Cristian Smerdou et al.   MOLECULAR THERAPY

Lipid accumulation and dendritic cell dysfunction in cancer

(2010) Donna L Herber et al.   NATURE MEDICINE

RIGorous Detection: Exposing Virus Through RNA Sensing

(2010) J. Rehwinkel et al.   SCIENCE

Alphavirus vectors for cancer therapy

(2010) Jose I. Quetglas et al.   VIRUS RESEARCH

Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells

(2009) Damià Tormo et al.   CANCER CELL

Targeted genetic and viral therapy for advanced head and neck cancers

(2009) Pin-I Huang et al.   DRUG DISCOVERY TODAY

Alphaviruses in Gene Therapy

(2009) Kenneth Lundstrom   Viruses-Basel

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

(2008) R. Houot et al.   BLOOD

MDA5/RIG-I and virus recognition

(2008) Osamu Takeuchi et al.   CURRENT OPINION IN IMMUNOLOGY

Oncolytic viruses: a novel form of immunotherapy

(2008) Robin J Prestwich et al.   Expert Review of Anticancer Therapy

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

(2008) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

(2008) K. Hildner et al.   SCIENCE